SUCLA2

Across TCGA pan-cancer cohorts, SUCLA2 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated SUCLA2 data layer compared with 23 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher SUCLA2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated SUCLA2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC and CCRCC are the cancer types where SUCLA2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	All	0.952	0.701	<.001	30	view →
CCRCC	DFS	Median	III,IV	1.000	0.280	.022	8	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

SUCLA2–PDAC (OS)

Open the PDAC breakdown →